Combination of Keytruda and Yervoy does not improve cancer survival, MSD trial finds
pharmafile | February 2, 2021 | News story | Manufacturing and Production | Cancer, MSD
A new trial by Merck – known as MSD outside of North America – has found that their lung cancer treatment, Keytruda (pembrolizumab), does not increase overall survival rate when paired with the melanoma medicine Yervoy.
The Phase III KEYNOTE-598 trial found that, rather than improve the survival rate, the combination with Yervoy (ipilimumab) added toxicity compared with patients who only received Keytruda.
In the randomised, double-blind study of 568 patients, where half each received a different treatment, the median overall survival was 21.9 months for patients randomised to just Keytruda, compared with 21.4 months for patients on a combination of the two therapies.
The addition of Yervoy also increased the likelihood of the patients receiving serious side effects, with 76.2% experiencing adverse symptoms related to the treatment, as opposed to 68.3% of those on just Keytruda.
Dr. Roy Baynes, Senior Vice President and Head of Global Development at MSD, said: “As a leader in lung cancer, we are pursuing a broad clinical program to better understand the potential of Keytruda-based combinations to improve survival outcomes for patients with this devastating disease.
“KEYNOTE-598 is the first head-to-head study designed to answer the question of whether combining Keytruda with ipilimumab provided additional clinical benefits beyond treatment with Keytruda alone in certain patients with metastatic non-small cell lung cancer. The results are clear – the combination did not add clinical benefit but did add toxicity.”
Jack Goddard
Related Content
Central nervous system cancer metastases – the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds
BioMed X and Servier launch Europe’s first XSeed Labs to advance AI-powered antibody design
BioMed X and Servier have announced the launch of Europe’s first XSeed Labs research project, …
T-cell therapy – the evolution of cancer treatments
The current forms of immunotherapy, how T cell therapy works and what the future holds
